|
Main
|
|
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
17 October 2012 |
|
Main ID: |
NCT01020253 |
|
Date of registration:
|
24/11/2009 |
|
Primary sponsor: |
|
|
Public title:
|
The Effectiveness of Two Osteoporosis Drugs on Prosthetic Bone Mineral Density (BMD) Loss After Total Hip Arthroplasty(THA)
ETOD |
|
Scientific title:
|
A Comparison of Alendronate vs. Alfacalcidol Medication for the Preservation of Bone Mineral Density Around the Femoral Implant and in the Lumbar Spine After a Total Hip Arthroplasty |
|
Date of first enrolment:
|
January 2006 |
|
Target sample size:
|
60 |
|
Recruitment status: |
Active, not recruiting |
|
URL:
|
http://clinicaltrials.gov/show/NCT01020253 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
|
|
|
Countries of recruitment
|
|
Japan
| | | | | | | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- osteoarthritis of the hip
- patients after total hip arthroplasty
Exclusion Criteria:
- diseases related to bone metabolism
- patients taking drugs which affect bone metabolism
Age minimum:
44 Years
Age maximum:
82 Years
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Arthroplasty, Replacement, Hip
|
|
Bone Density
|
|
Intervention(s)
|
|
Drug: alendronate, alfacalcidol
|
|
Primary Outcome(s)
|
|
DEXA QDR 2000, Hologic Co.
[Time Frame: 1, 12, 24 and 48 weeks after operation]
|
|
Secondary ID(s)
|
|
YCU07-122
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|